Hepatocellular carcinoma, characterized by a low TP53 mutation rate but frequent functional inactivation of wt-p53 through dysregulated post-translational modifications (PTMs), presents a critical challenge in oncology [24]. This evidence concerns the gene TP53 and hepatocellular carcinoma.